Sound Income Strategies LLC Has $934,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Sound Income Strategies LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,456 shares of the company’s stock after selling 202 shares during the period. Sound Income Strategies LLC’s holdings in Johnson & Johnson were worth $934,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Dark Forest Capital Management LP bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $223,000. Bontempo Ohly Capital Mgmt LLC boosted its stake in Johnson & Johnson by 0.8% during the 2nd quarter. Bontempo Ohly Capital Mgmt LLC now owns 14,650 shares of the company’s stock valued at $2,141,000 after purchasing an additional 115 shares during the period. Magnolia Capital Advisors LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $21,803,000. Nemes Rush Group LLC boosted its stake in Johnson & Johnson by 4.4% during the 2nd quarter. Nemes Rush Group LLC now owns 51,269 shares of the company’s stock valued at $7,494,000 after purchasing an additional 2,171 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in Johnson & Johnson by 11.5% during the 2nd quarter. NewEdge Advisors LLC now owns 268,520 shares of the company’s stock valued at $39,247,000 after purchasing an additional 27,704 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Barclays reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Insider Activity

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

JNJ stock opened at $146.76 on Monday. The business has a fifty day moving average price of $147.85 and a 200 day moving average price of $156.06. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock has a market capitalization of $353.34 billion, a price-to-earnings ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period last year, the firm posted $2.29 EPS. The business’s revenue was up 5.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.